Eagle Pharmaceuticals, Inc. (EGRX)
EGRX Stock Price Chart
Explore Eagle Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze EGRX price movements and trends.
EGRX Company Profile
Discover essential business fundamentals and corporate details for Eagle Pharmaceuticals, Inc. (EGRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
12 Feb 2014
Employees
134.00
Website
https://www.eagleus.comCEO
Michael Graves
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
EGRX Financial Timeline
Browse a chronological timeline of Eagle Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 13 Nov 2024
Earnings released on 26 Aug 2024
Earnings released on 22 May 2024
Earnings released on 28 Mar 2024
Earnings released on 9 Nov 2023
EPS came in at -$0.27 falling short of the estimated $1.09 by -124.77%.
Earnings released on 8 Aug 2023
EPS came in at $1.18 surpassing the estimated $1.05 by +12.38%, while revenue for the quarter reached $64.65M , beating expectations by +8.90%.
Earnings released on 9 May 2023
EPS came in at $1.26 surpassing the estimated $1.19 by +5.88%, while revenue for the quarter reached $66.31M , beating expectations by +4.76%.
Earnings released on 13 Mar 2023
EPS came in at $1.10 surpassing the estimated $0.78 by +41.03%, while revenue for the quarter reached $60.70M , missing expectations by -5.54%.
Earnings released on 7 Nov 2022
EPS came in at $1.12 surpassing the estimated $0.84 by +33.33%, while revenue for the quarter reached $65.90M , beating expectations by +5.93%.
Earnings released on 9 Aug 2022
EPS came in at $1.56 falling short of the estimated $3.13 by -50.16%, while revenue for the quarter reached $74.14M , missing expectations by -36.61%.
Earnings released on 9 May 2022
EPS came in at $4.04 surpassing the estimated $3.88 by +4.12%, while revenue for the quarter reached $115.87M , missing expectations by -6.04%.
Earnings released on 7 Mar 2022
EPS came in at $0.85 falling short of the estimated $0.87 by -2.30%, while revenue for the quarter reached $42.32M , missing expectations by -17.15%.
Earnings released on 9 Nov 2021
EPS came in at $0.56 falling short of the estimated $0.87 by -35.63%, while revenue for the quarter reached $39.85M , missing expectations by -14.11%.
Earnings released on 9 Aug 2021
EPS came in at $0.93 surpassing the estimated $0.88 by +5.68%, while revenue for the quarter reached $48.12M , beating expectations by +4.94%.
Earnings released on 10 May 2021
EPS came in at $0.24 falling short of the estimated $0.72 by -66.67%, while revenue for the quarter reached $41.25M , missing expectations by -31.87%.
Earnings released on 2 Mar 2021
EPS came in at $0.96 surpassing the estimated -$0.43 by +323.26%, while revenue for the quarter reached $49.92M .
Earnings released on 2 Nov 2020
EPS came in at $1.17 surpassing the estimated $0.29 by +303.45%, while revenue for the quarter reached $49.93M , beating expectations by +290.00%.
EGRX Stock Performance
Access detailed EGRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.